Rhythm Pharmaceuticals: Exciting Times With sNDA PDUFA Date [Seeking Alpha]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Seeking Alpha
RYTM's market opportunity could double or triple with AHO approval, but patent life for IMCIVREE is limited, prompting focus on next-generation therapies. Current liquidity provides a 24-month runway, but additional financing may be needed unless revenues or out-licensing deals improve the cash position. Given near-term consolidation and patent risks, I downgrade RYTM from 'Buy' to 'Hold,' while remaining optimistic about long-term prospects. H. Armstrong Roberts/Retrofile RF via Getty Images This is my third Rhythm ( NASDAQ: RYTM ) article, following 06/2025's "Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects." In Excellent Prospects , I rated Rhythm as a "Buy." It has since enjoyed a tasty ~52% bump. In this article, I will assess its forward prospects This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of RYTM either through stock ownership, options, or other derivatives. I wrote this article
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.MarketBeat
- Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]Seeking Alpha
- Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 11/4/25 - Miss
RYTM
Sec Filings
- 11/24/25 - Form 4
- 11/20/25 - Form 144
- 11/14/25 - Form SCHEDULE
- RYTM's page on the SEC website